Novo Nordisk's new obesity drug, CagriSema, has disappointed investors with trial results showing lower-than-expected weight loss, leading to a 20% drop in share price and concerns about competitiveness in the market. The company plans to explore further weight loss potential and has upcoming trials expected in 2025. Teljes cikk (Euronews.com)